Bioventix: delightful as always
This highly unusual company continues to deliver excellent results and wonderful cash flow. We are also impressed with the clear explanation provided of their somewhat complicated activities; other AIM companies should take note. Read on here to find out more about this delightful company.
Bioventix (AIM:BVXP), which specialises in the area of antibodies for applications in clinical diagnostics, has announced excellent results for its financial year ending 30 June 2023. This is a highly unusual AIM company, which we first covered in 2015, since when the shares have climbed over 350% and paid out substantial dividends as well. So what’s so unusual about this business? Bioventix creates and manufactures high affinity sheep monoclonal antibodies (‘SMAs’) for use in diagnostic applications. Bioventix antibodies are preferred for use when they confer an improved test performance compared to other available antibodies. The Group was founded in 2003…